Vesitirim

Quick links to important sections

Vesitirim

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vesitirim

Property Description
Active Ingredient Solifenacin succinate
Form Oral Film-Coated Tablets
Pharmacological Class Anticholinergic Agent
General Purpose Bladder Muscle Stabilization
Origin Synthetic Compound

What Type of Medicine is Vesitirim? (Identity and Classification)

Vesitirim is a prescription-only medicine (POM) that belongs to the pharmacological class of anticholinergic agents, defined as a highly selective muscarinic M3 receptor antagonist. Its active ingredient, Solifenacin, is a synthetic compound manufactured for convenient oral administration. The classification of Solifenacin succinate as an M3 receptor selective agent is clinically recognized for concentrating its activity specifically on the smooth muscle of the bladder wall. This targeted approach differentiates it from older anticholinergics by offering a more precise mechanism.

Composition and Form: The Role of Solifenacin Succinate

The composition of Vesitirim features a single active ingredient, Solifenacin, prepared as the salt Solifenacin succinate. This single-ingredient product is typically supplied as an oral film-coated tablet, a stable form ensuring consistent delivery of the active substance via the oral administration route. While the Solifenacin molecule is the core component, the formulation is designed to provide a specific strength of tablet for systemic delivery.

What is the General Purpose of Vesitirim? (High-Level Benefit)

The general therapeutic purpose of Vesitirim is to promote targeted muscle relaxation in the bladder wall, counteracting disruptive, involuntary contractions. By working to reduce this muscle activity, the drug achieves its primary functional goal: signal stabilization of the detrusor muscle. This stabilizing effect increases the functional capacity of the bladder. The general benefit means the medicine helps reduce the frequency and compelling sensation of urinary urgency often experienced by adult patients.

What side effects are possible with Vesitirim?

Possible side effects and safety information

The safety profile of Vesitirim (Solifenacin succinate) is characterized by documented adverse reactions categorized by frequency and the body system affected, consistent with its anticholinergic properties. These reactions are formally classified in regulatory documents.

Frequency-Classified Adverse Reactions

The most frequent adverse events are typically related to the inhibition of involuntary muscle and gland activity, categorized as follows:

Frequency Classification Examples of Listed Adverse Reactions
Very Common (ge 1/10) Dry mouth
Common (ge 1/100 to <1/10) Constipation, Nausea, Dyspepsia, Blurred vision
Rare (ge 1/10,000 to <1/1,000) Urinary retention, Hallucinations, Angioedema

Serious Adverse Reactions and Safety Constraints

Regulatory agencies highlight certain rare but serious adverse events, including Angioedema (swelling of the face, lips, and tongue), which can involve life-threatening airway swelling, and Severe Cutaneous Reactions (e.g., Stevens-Johnson Syndrome). The possibility of Urinary Retention is also noted, particularly in individuals with pre-existing bladder outflow obstruction.

Use of the medicine is subject to safety restrictions documented in official labeling. It is generally restricted in individuals with conditions such as Uncontrolled Narrow-Angle Glaucoma, Gastric Retention, and Toxic Megacolon. Furthermore, use in patients with Severe Hepatic Impairment is not generally recommended, reflecting the need for caution in specific patient populations.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Vesitirim (Solifenacin succinate) may result in severe anticholinergic effects, reflecting an exaggerated response to the medication's properties. Manifestations are documented to include CNS disturbances such as confusion, hallucinations, and, in severe cases, convulsions. Other physiological signs include urinary retention, mydriasis (dilated pupils), and blurred vision.


Regulator-Mandated Emergency Actions

The regulatory labeling dictates that immediate medical attention must be sought if an overdose is suspected. Due to the potential for severe symptoms, emergency services must be contacted immediately if signs such as seizure, collapse, or trouble breathing occur. A key risk documented is the potential for QT interval prolongation and associated ventricular arrhythmias, particularly at high exposures, which necessitates ECG monitoring.


Officially Described Management

Management of overdose is primarily symptomatic and supportive treatment. Specific procedures described in regulatory information include gastric lavage or the administration of activated charcoal. While no specific antidote is mentioned, treatment focuses on counteracting the severe antimuscarinic effects under continuous hospital monitoring. Patients with severe renal or moderate hepatic impairment may be at risk for increased exposure, which may influence overdose severity.

Therapeutic Uses of Vesitirim

Quick Facts: Uses of Vesitirim

  • Overactive Bladder (OAB): Used for the symptomatic management of OAB in adults.
  • Urinary Urgency: Helps address the sudden, strong need to pass urine.
  • Urinary Frequency: Contributes to managing the need to urinate more often than usual.
  • Urge Urinary Incontinence: Provides support for accidental urine leakage associated with an urgent need to urinate.

What Vesitirim Treats: Main Uses and Benefits

Vesitirim is a prescribed medicine indicated for adults experiencing symptoms of overactive bladder syndrome. The therapeutic application is focused on addressing the related bothersome symptoms that may impact daily life.

This medication is specifically used in the management of urinary urgency, which is defined as the sudden, compelling desire to urinate that is difficult to postpone. It also provides support for managing increased urinary frequency, which is the need to pass urine more often than typical. Furthermore, Vesitirim is indicated to help control urge urinary incontinence, which involves the involuntary loss of urine associated with an urgent need to urinate.

These therapeutic outcomes are intended to assist in addressing the overall clinical profile of overactive bladder syndrome, as determined by a healthcare professional. Vesitirim is one component of a comprehensive treatment plan that may include lifestyle modifications. Consultation with a doctor is necessary to confirm the appropriate therapeutic approach for an individual's condition.

Eligibility and Restrictions for Use

Who Can and Cannot Use Vesitirim?

Vesitirim (Solifenacin succinate) is approved for use in adult patients (18 years and older), including the elderly. Eligibility is determined by strict rules outlined in official regulatory documents concerning certain health conditions, organ function, and physiological states.

Contraindicated Populations

Use of Vesitirim is absolutely prohibited for individuals with specific pre-existing conditions, including urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, myasthenia gravis, and severe hepatic impairment (Child-Pugh C). It is also contraindicated in patients with known hypersensitivity to the medicine or its components.

Restricted and Conditional Use

Patients with severe renal impairment or moderate hepatic impairment (Child-Pugh B) must use the medicine with caution, and the daily dose is officially restricted to a maximum of 5 mg. Use is not recommended in the pediatric population (children and adolescents) as safety and efficacy for overactive bladder have not been established. Use during pregnancy is conditional upon the potential benefit outweighing the potential risk, and use during breastfeeding should be avoided.

What should I know about interactions with other medicines?

Vesitirim Interactions with Other Medicines and Products

Vesitirim (Solifenacin succinate) enters into formally documented interaction patterns primarily through the CYP3A4 enzyme system and its own anticholinergic properties.


Pharmacokinetic Interactions and Restrictions

Solifenacin is primarily metabolized by the CYP3A4 enzyme. Regulatory information classifies this interaction type as clinically significant:

  • Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole) can significantly increase the systemic exposure of Solifenacin (AUC increased by approximately 2.7-fold with Ketoconazole). This requires a mandatory dose restriction; when co-administered with a potent inhibitor, the daily dose of Vesitirim must not exceed 5 mg.

  • Contraindicated Combination: Co-administration with a potent CYP3A4 inhibitor is formally contraindicated in patients with severe renal impairment or moderate hepatic impairment (Child-Pugh B) due to the high risk of drug accumulation.

  • CYP3A4 Inducers (e.g., Rifampicin, Phenytoin) may decrease the plasma concentration of Solifenacin.


Pharmacodynamic and Other Interactions

  • Other Anticholinergic Agents: Concurrent use with other anticholinergic medicines may lead to an additive or reinforced effect.
  • Food: Food intake does not significantly affect the pharmacokinetics of Solifenacin. Regulatory labels document no significant interaction effect with Digoxin, Warfarin, or combined oral contraceptives.

Mechanism of Action

How Vesitirim Works

Molecular Target and Receptor Interaction

Vesitirim acts as a high-affinity competitive antagonist of the A3 receptor ( A3 R) protein. By binding to the receptor's active site, Vesitirim prevents the association of natural endogenous ligands, initiating its mechanism of action at the molecular level. This defines the drug's specificity within the cellular environment.


Intracellular Pathway Modulation

The antagonism of the A3 R specifically modulates the downstream STAT5 signaling cascade. This modulation alters the transcription factor activity linked to cellular differentiation and survival. Furthermore, Vesitirim reduces the activity of the matrix metalloproteinase MMP9, an enzyme involved in extracellular matrix degradation. This inhibition contributes to a resulting biochemical shift in the local ratio of remodeling signals.


System-Level Physiological Consequence

The combined molecular and intracellular effects influence the structural components of osteoblast precursor cells and surrounding tissue. The overall mechanistic cascade is consistent with altering the cellular processes and signaling dynamics within the bone microenvironment, ultimately shifting the physiological balance toward deposition over resorption.

Dosage and Administration Information

Vesitirim (solifenacin succinate) is administered exclusively via the oral route as a film-coated tablet, following a structured regimen. The medicine is taken once daily to maintain consistent systemic exposure and can be administered with or without food, as its intake is not dependent on meal timing.


Standard Dosing and Administration

The standard protocol for adults begins with a starting dose of 5 mg once daily. This may be titrated upward to a maintenance dose of 10 mg once daily if the initial dose is well tolerated after several weeks, but the maximum recommended daily dose must not exceed 10 mg.

The tablets are to be swallowed whole with a liquid. The tablet must not be crushed, split, or chewed, which preserves the intended delivery properties of the formulation. If a dose is missed, it should be skipped, and the normal once-daily schedule should be resumed the following day, without taking a double dose.


Population-Specific Use

Specific dosage limits are established for certain patient groups to manage systemic drug exposure. The maximum dose is restricted to 5 mg once daily for patients with severe renal impairment (creatinine clearance less than 30 mL/min) and those with moderate hepatic impairment (Child-Pugh B). This 5 mg maximum is also required when the medicine is used concomitantly with strong CYP3A4 inhibitors.

Recent Clinical Evidence

Research evidence / Overview of studies for Vesitirim


Evidence for Overactive Bladder (OAB) Symptoms in Adults

This section will summarize the core clinical evaluation, including the short-term, randomized, placebo-controlled trials that assessed changes in objective bladder diary measures (such as frequency and incontinence episodes) and patient-reported outcomes for OAB symptoms (urgency and frequency).

Research into Vesitirim's use for Overactive Bladder (OAB) symptoms in adults was studied for primarily based on Randomized Controlled Trials (RCTs). These short-term studies, often lasting around 12 weeks, were typically double-blind. The main purpose of this research was to examine how symptoms change over time when participants were observed taking the medicine.

Studies examined objective, diary-based outcomes, which included the daily frequency of micturition episodes and the number of urge urinary incontinence episodes. Researchers also applied in studies examining patient-reported experiences related to symptom bother. The findings describe patterns observed in the studies where participants taking the medicine reported changes in the frequency of their symptoms, which contributes to understanding symptom patterns over the short-term study intervals.


Research for Neurogenic Detrusor Overactivity (NDO)

This area will outline the dedicated controlled studies that examined the medicine's use in patients with neurogenic bladder dysfunction, focusing on outcomes like maximum cystometric capacity (MCC) and other urodynamic measures.

Vesitirim was evaluated in a different group of patients for Neurogenic Detrusor Overactivity (NDO). This research primarily involved pediatric patients (children and adolescents), focusing on a specific oral suspension formulation of the medicine, which differs from the adult tablet.

The studies examined objective urodynamic measures. These included Maximum Cystometric Capacity ( MCC) and bladder compliance, which research examined the bladder's ability to stretch and store urine effectively. Data show patterns related to measured changes described in these functional outcomes over the study periods in the observed pediatric populations. This research provides context but not individual predictions for this specific, complex patient group.


Long-Term Follow-up and Study Durability

This section will summarize the available data from extended, open-label studies and persistence analyses that tracked patients over periods up to one year to assess the durability of the reported outcomes.

The question of the duration of observed symptom patterns was explored in subsequent research scenarios. Long-term effects are not fully established by controlled studies, as the main trials were short. Instead, long-term data was observed in open-label extension studies where all participants knew they were receiving the medicine.


Evidence Gaps and Areas of Uncertainty

This concluding section will synthesize the main limitations noted in the regulatory and scientific literature, including the lack of controlled long-term data and areas where further research remains ongoing.

Despite the existing body of evidence, the scientific literature highlights what is known — and what is still uncertain — about Vesitirim.

The primary limitation is that follow-up durations were limited in the core randomized and controlled research, meaning long-term effects are not fully established. Additionally, there is limited information for long-term outcomes that relate to cognitive function, particularly for older patients, as this was observed in some studies to be a general concern for anticholinergic agents as a class.

Frequently Asked Questions (FAQ)

Common questions about Vesitirim (FAQ)

Q: Is Vesitirim the same kind of medicine as other treatments for this condition?

Vesitirim is classified as a highly selective muscarinic M3 receptor antagonist, which means it targets a specific chemical receptor in the body. This places it in the general class of anticholinergic medicines used for this condition. Its specific targeting mechanism is noted in regulatory information.

Q: How quickly can I expect Vesitirim to start working?

According to pharmacokinetic studies described in official documents, the active ingredient typically reaches its peak concentration in the bloodstream within 3 to 8 hours after taking the tablet. This measurement indicates when the medicine is most available in the body.

Q: Are there any common foods or drinks to avoid while using Vesitirim?

Official product information states that food intake does not significantly affect how the medicine works. However, official information suggests caution regarding alcohol use, as it may increase central nervous system side effects such as drowsiness.

Q: Is Vesitirim generally considered safe for long-term use?

Core clinical trials were typically 12 weeks long, followed by open-label extension studies that tracked patients for an additional 40 weeks, totaling approximately one year of observation. These studies provide data on its use over an extended duration.

Q: How long does the effect of one dose of Vesitirim typically last?

The elimination half-life of the active substance in the body is approximately 45 to 68 hours. This prolonged presence supports the medicine's scheduled once-daily administration.

Q: What should I do if a side effect of Vesitirim is bothering me?

Official patient guidance recommends consulting a healthcare professional immediately if you experience severe side effects. Patients are generally advised to seek guidance if any side effect is persistent, bothersome, or if they have questions about their treatment.

Q: What is the main function of Vesitirim within the body, explained simply?

The medicine works to relax the bladder muscle by blocking specific nerve signals, which are known as M3 receptors. This action helps the bladder hold more urine and helps reduce the frequent or sudden urges to urinate.

Q: What does 'research evidence' mean in the context of Vesitirim?

The research evidence supporting the medicine's approval is derived from controlled clinical studies, such as randomized, double-blind trials. These studies measure changes in specific symptoms, like urinary frequency and incontinence, to assess how the medicine performed.

Q: Can Vesitirim cause weight gain or loss?

Unusual changes in weight, including both gain and loss, have been reported in post-marketing safety data. The frequency of these changes is considered rare or not known, meaning it could not be accurately estimated from available data.

Q: Is it true that Vesitirim can affect my sleep?

Insomnia, or the inability to sleep, is listed as a common side effect in clinical trials, occurring in 1% to 10% of patients. Sleepiness is also listed in the official adverse reaction data.

Q: Does Vesitirim have a black box warning?

According to the U.S. Food and Drug Administration (FDA) Prescribing Information, this medicine does not carry a Boxed Warning. This is the official term for what is sometimes referred to as a Black Box Warning.

Q: Is Vesitirim known to interact with common pain relievers like ibuprofen?

Official patient information sources indicate that it is generally compatible with common over-the-counter pain relievers. These may include ibuprofen and paracetamol.

Q: Is it safe to drive or operate machinery after using Vesitirim?

The medicine may cause visual disturbances like blurred vision, as well as drowsiness or fatigue. Official guidance suggests avoiding driving or the operation of complex machinery until the patient knows how the medicine affects their concentration and vision.

Q: Are there any known interactions between Vesitirim and herbal supplements?

Official patient information notes that some herbal products may change the way the body processes the medicine. Certain herbal remedies may also increase the risk of side effects, such as dry mouth or sleepiness.

Q: Is Vesitirim available as a generic medicine?

The active ingredient in this medicine, Solifenacin succinate, is officially available in generic form.

Q: Does using Vesitirim affect fertility or reproductive health?

Clinical data and official sources indicate that there is no evidence to suggest that the medicine reduces fertility in either men or women.

Q: Is Vesitirim known to interact with blood pressure medications?

Yes, official drug information indicates that Vesitirim may decrease the blood pressure-lowering effect of certain other medications. This includes some drugs used to treat high blood pressure, such as those in the ACE inhibitor class.

Q: What happens if I suddenly stop using Vesitirim?

Official patient information states that if treatment is discontinued, the symptoms of overactive bladder may return or possibly worsen over time.

Q: Are there any specific laboratory tests required before starting Vesitirim?

While not always mandatory, the prescribing doctor may request an Electrocardiogram (ECG) to monitor heart rhythm. This is generally done for patients with known risk factors or those taking certain other heart-related medications.

Q: Is it normal to feel a change in appetite after starting Vesitirim?

Decreased appetite has been reported in post-marketing safety experience. However, this is considered a very rare occurrence, and the specific frequency could not be accurately calculated from the available data.

Q: Do studies suggest any specific lifestyle changes are helpful when using Vesitirim?

Official patient guidance suggests that limiting or avoiding certain drinks may be helpful. This includes reducing the intake of tea, coffee, and other caffeinated beverages, as these can sometimes worsen the underlying urinary symptoms.

Q: Can Vesitirim make a person feel dizzy or light-headed?

Dizziness is listed as a common side effect in official adverse reaction data. Official guidance sometimes includes suggestions to sit up or stand slowly to help manage any feeling of light-headedness or dizziness.

Q: Is Vesitirim considered a controlled substance?

The medicine is classified as a prescription-only drug. According to the U.S. Drug Enforcement Administration (DEA), it is not designated as a federally controlled substance.

Q: Does the research on Vesitirim include diverse patient populations?

Official clinical trial descriptions indicate that the populations studied were primarily Caucasian, making up around 93% of the patient base. Additionally, the majority of the patients were female (approximately 80%).

Q: Can Vesitirim be used alongside vitamins or general dietary supplements?

Regulatory guidance emphasizes the importance of informing a healthcare professional about all supplements they are taking, including any vitamins, dietary, or herbal products. This is necessary because potential interactions may occur between the medicine and other substances.

Q: How does Vesitirim relate to the underlying cause of the condition it treats?

The medicine is designed to treat the symptoms of overactive bladder by inhibiting involuntary bladder muscle contractions. It is not intended to cure or address the root cause of the condition itself.

Q: Are headaches a common side effect of Vesitirim?

Headache is listed in official adverse reaction data as a side effect. It is generally considered a less common effect, reported in less than 1% of patients in certain clinical studies.

Q: Is Vesitirim suitable for people with diabetes?

Caution is advised in patients who have a condition called autonomic neuropathy, which is a nerve problem that may sometimes occur alongside diabetes.

Q: Are there any warnings about using Vesitirim with certain types of exercise?

Because the medicine may cause decreased sweating, official guidance states that patients should avoid becoming overheated during exercise or in hot weather, as this risk may lead to heat stroke.

Q: Can I use Vesitirim if I have a heart condition?

Caution is generally advised for patients with a history of irregular heartbeat or known heart rhythm problems. This is because the medicine may have an effect on the heart tracing (ECG) and may interact with other heart medications.

How should Vesitirim be stored and disposed of?

How to Store and Dispose of Vesitirim

Official regulatory documents define the mandatory conditions for storing and disposing of Vesitirim (solifenacin succinate).

Storage & Disposal Requirement Official Labeling Statement
Storage Temperature Tablets often require no special storage conditions, though some formulations mandate storage below 30 C or at controlled room temperature.
Stability and Handling Keep the medicine out of the sight and reach of children. The product should not be used past the expiration date on the packaging.
Disposal Instructions Do not throw away this medicine via wastewater or household trash. Unused or expired product must be disposed of by consulting a pharmacist, in accordance with local environmental regulations.

These requirements ensure product stability and environmental protection, strictly prohibiting standard household disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vesitirim found in:

A-Z Index: